RhumbLine Advisers’s Insys Therapeutics, Inc. INSY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-49,222
| Closed | -$227K | – | 3059 |
|
|
2019
Q1 | $227K | Buy |
49,222
+12,400
| +34% | +$58.7K | ﹤0.01% | 2696 |
|
|
2018
Q4 | $129K | Buy |
36,822
+11,657
| +46% | +$81K | ﹤0.01% | 2843 |
|
|
2018
Q3 | $254K | Sell |
25,165
-1,725
| -6% | -$13.8K | ﹤0.01% | 2605 |
|
|
2018
Q2 | $195K | Buy |
26,890
+2,960
| +12% | +$20.6K | ﹤0.01% | 2743 |
|
|
2018
Q1 | $145K | Sell |
23,930
-775
| -3% | -$6.4K | ﹤0.01% | 2679 |
|
|
2017
Q4 | $238K | Sell |
24,705
-7,140
| -22% | -$46.7K | ﹤0.01% | 2558 |
|
|
2017
Q3 | $283K | Buy |
31,845
+875
| +3% | +$9.03K | ﹤0.01% | 2581 |
|
|
2017
Q2 | $392K | Buy |
30,970
+1,793
| +6% | +$21.2K | ﹤0.01% | 2430 |
|
|
2017
Q1 | $307K | Buy |
29,177
+433
| +2% | +$4.61K | ﹤0.01% | 2497 |
|
|
2016
Q4 | $264K | Buy |
28,744
+1,004
| +4% | +$11.3K | ﹤0.01% | 2549 |
|
|
2016
Q3 | $327K | Sell |
27,740
-400
| -1% | -$6.08K | ﹤0.01% | 2434 |
|
|
2016
Q2 | $364K | Buy |
28,140
+1,885
| +7% | +$27.5K | ﹤0.01% | 2403 |
|
|
2016
Q1 | $420K | Buy |
26,255
+790
| +3% | +$15K | ﹤0.01% | 2340 |
|
|
2015
Q4 | $729K | Buy |
25,465
+2,065
| +9% | +$57.2K | ﹤0.01% | 2012 |
|
|
2015
Q3 | $666K | Sell |
23,400
-62
| -0.3% | -$2.28K | ﹤0.01% | 2045 |
|
|
2015
Q2 | $843K | Buy |
23,462
+2,620
| +13% | +$81.6K | ﹤0.01% | 1980 |
|
|
2015
Q1 | $606K | Buy |
20,842
+2,650
| +15% | +$70.1K | ﹤0.01% | 2175 |
|
|
2014
Q4 | $383K | Buy |
18,192
+300
| +2% | +$5.93K | ﹤0.01% | 2437 |
|
|
2014
Q3 | $347K | Buy |
17,892
+240
| +1% | +$3.77K | ﹤0.01% | 2439 |
|
|
2014
Q2 | $276K | Buy |
17,652
+3,778
| +27% | +$61.1K | ﹤0.01% | 2650 |
|
|
2014
Q1 | $287K | Buy |
+13,874
| New | +$275K | ﹤0.01% | 2563 |
|
Other funds holding INSY
WS
RhumbLine Advisers's INSY Position: Q2 2019 in Review
RhumbLine Advisers sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 49,222 shares — an estimated $227K sold.
RhumbLine Advisers first reported a position in INSY in Q1 2014 and held it in 21 quarters. The position peaked at $843K in Q2 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.
- RhumbLine Advisers reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
- RhumbLine Advisers sold 49,222 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $227K.
- RhumbLine Advisers first reported a position in Insys Therapeutics, Inc. in Q1 2014 and held it in 21 quarters.
- RhumbLine Advisers's Insys Therapeutics, Inc. position peaked at $843K in Q2 2015.
- 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.
Based on RhumbLine Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.